Physician profile
Melissa Notemyer
NPI 1710473558
$557.28
in general payments reported to CMS, 2019-2025
14 companies · $78.32 in 2025
The $78.32 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.70 · 2022: $140 · 2023: $126 · 2024: $154 · 2025: $78.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $87.58 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $63.14 | 2022-2024 | Vaxelis, Gardasil 9, Gardasil |
| Ironshore Pharmaceuticals INC. | $61.69 | 2023-2024 | Jornay Pm |
| Cranial Technologies, INC | $60.26 | 2022-2025 | Doc Band |
| Seqirus USA INC | $52.04 | 2022-2025 | Flucelvax Quadrivalent, Flucelvax |
| Supernus Pharmaceuticals, INC. | $47.02 | 2021 | |
| Pfizer INC. | $42.77 | 2023-2025 | |
| Tris Pharma INC | $42.38 | 2022 | |
| Sobi, INC | $27.40 | 2022-2023 | |
| Phadia US INC. | $17.93 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.65 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $12.84 | 2023 | |
| Mylan Pharmaceuticals INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Notemyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.